Related Experiment Video

Updated: Dec 5, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.5K

Current and emerging biologics for the treatment of pediatric atopic dermatitis

Rima Ghamrawi1, Katheryn A Bell1, Esther A Balogh1

  • 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem, NC, USA.

Expert Opinion on Biological Therapy
|October 20, 2020
PubMed

Insights

Biologics offer new hope for treating pediatric atopic dermatitis (AD), a chronic inflammatory skin condition. While promising, further research is needed to understand the long-term effects of these advanced therapies in children.

Area of Science:

  • Dermatology
  • Immunology
  • Pediatrics

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition in children, marked by redness, itching, and skin barrier issues.
  • Current treatments for pediatric AD have limitations in efficacy and safety, with few systemic options available.
  • Advancements in understanding AD pathogenesis have led to the development of targeted biologic therapies.

Purpose of the Study:

  • To review current and emerging biologic therapies for pediatric atopic dermatitis (AD).
  • To provide a comprehensive comparison of biologic medications and their clinical trials.
  • To offer expert insights into future advancements in treating pediatric AD.

Main Methods:

  • Literature review of current and emerging biologic therapies for pediatric AD.
  • Analysis of clinical trial data for efficacy and safety of biologic agents.
  • Expert opinion on the use of biologics in the pediatric population.

Main Results:

  • Several biologic agents are in clinical trials for pediatric AD, offering new treatment avenues.
  • Dupilumab has existing safety data, positioning newer biologics likely as second-line options.
  • The long-term impact and risks of novel biologics on children's immature immune systems require further investigation.

Conclusions:

  • Biologics represent a promising frontier for managing pediatric atopic dermatitis.
  • Cautious optimism and continued research are essential for the safe and effective integration of biologics in treating children with AD.
  • Optimizing patient treatment plans requires a thorough understanding of available and emerging biologic therapies.
Abstract

Keywords:
Atopic dermatitisatopic eczemabiologicsclinical trialsdupilumablebrikizumabnemolizumabpediatricrisankizumabtralokinumab

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.6K
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

4.5K

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
145
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
325
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
335
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
138
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K